Literature DB >> 29936467

Expression of SOX9 Is Related to Prognosis in Patients with Oesophageal Squamous Cell Carcinoma.

Naotomo Higo1, Hiroshi Okumura2, Yasuto Uchikado1, Itaru Omoto1, Ken Sasaki1, Yoshiaki Kita1, Desaki Ryosuke1, Masahiro Noda1, Tetsuhiro Owaki1, Sumiya Ishigami1, Shoji Natsugoe1.   

Abstract

BACKGROUND: Sex-determining region Y-box 9 (SOX9) is an important transcription factor for the development and differentiation of cells and their organization. In the present study, the clinical significance of SOX9 expression in oesophageal squamous cell carcinoma was examined.
MATERIALS AND METHODS: SOX9 expression in surgical specimens of primary tumours were immunohistochemically investigated in 175 patients with oesophageal squamous cell carcinomas.
RESULTS: SOX9 was expressed (moderately or strongly) in 62.9% of samples. Expression of SOX9 was significantly positively correlated with depth of invasion, advanced stage, lymphatic and venous invasion, and poor prognosis. Univariate analysis showed that depth of invasion, lymph node metastasis, distant metastasis, stage, lymphatic invasion, venous invasion, and SOX9 expression were prognostic factors. Multivariate analysis indicated that depth of invasion and stage were independent prognostic factors, but SOX9 expression was not.
CONCLUSION: SOX9 expression is related to prognosis in patients with oesophageal squamous cell carcinoma, although it is not an independent prognostic factor. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  SOX9; oesophageal cancer; prognosis

Mesh:

Substances:

Year:  2018        PMID: 29936467      PMCID: PMC6117787          DOI: 10.21873/invivo.11316

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  12 in total

1.  Analysis of SOX9 expression in colorectal cancer.

Authors:  Bingjian Lü; Yihu Fang; Jing Xu; Lipei Wang; Fangying Xu; Enping Xu; Qiong Huang; Maode Lai
Journal:  Am J Clin Pathol       Date:  2008-12       Impact factor: 2.493

2.  SOXs in human prostate cancer: implication as progression and prognosis factors.

Authors:  Wei-de Zhong; Guo-qiang Qin; Qi-shan Dai; Zhao-dong Han; Shan-ming Chen; Xiao-hui Ling; Xin Fu; Chao Cai; Jia-hong Chen; Xi-bin Chen; Zhuo-yuan Lin; Ye-han Deng; Shu-lin Wu; Hui-chan He; Chin-lee Wu
Journal:  BMC Cancer       Date:  2012-06-15       Impact factor: 4.430

3.  Sox9 Controls Self-Renewal of Oncogene Targeted Cells and Links Tumor Initiation and Invasion.

Authors:  Jean-Christophe Larsimont; Khalil Kass Youssef; Adriana Sánchez-Danés; Vijayakumar Sukumaran; Matthieu Defrance; Benjamin Delatte; Mélanie Liagre; Pieter Baatsen; Jean-Christophe Marine; Saskia Lippens; Christopher Guerin; Véronique Del Marmol; Jean-Marie Vanderwinden; Francois Fuks; Cédric Blanpain
Journal:  Cell Stem Cell       Date:  2015-06-18       Impact factor: 24.633

4.  Elevated expression of SOX9 is related with the progression of gastric carcinoma.

Authors:  Cheng-Jun Zhou; Jian-Qiang Guo; Kong-Xi Zhu; Qing-Hui Zhang; Cheng-Ran Pan; Wei-Hua Xu; Hong-Juan Wang; Bin Liu
Journal:  Diagn Cytopathol       Date:  2011-02       Impact factor: 1.582

5.  Sox9 expression in carcinogenesis and its clinical significance in intrahepatic cholangiocarcinoma.

Authors:  Hajime Matsushima; Tamotsu Kuroki; Amane Kitasato; Tomohiko Adachi; Takayuki Tanaka; Masataka Hirabaru; Takanori Hirayama; Naoki Kuroshima; Masaaki Hidaka; Akihiko Soyama; Mitsuhisa Takatsuki; Naoe Kinoshita; Kazunori Sano; Noriyuki Nishida; Susumu Eguchi
Journal:  Dig Liver Dis       Date:  2015-08-18       Impact factor: 4.088

6.  Autosomal sex reversal and campomelic dysplasia are caused by mutations in and around the SRY-related gene SOX9.

Authors:  T Wagner; J Wirth; J Meyer; B Zabel; M Held; J Zimmer; J Pasantes; F D Bricarelli; J Keutel; E Hustert; U Wolf; N Tommerup; W Schempp; G Scherer
Journal:  Cell       Date:  1994-12-16       Impact factor: 41.582

7.  Expression features of SOX9 associate with tumor progression and poor prognosis of hepatocellular carcinoma.

Authors:  Xiaodong Guo; Lu Xiong; Ting Sun; Ruiyun Peng; Lin Zou; Haiyan Zhu; Jing Zhang; Hanwei Li; Jingmin Zhao
Journal:  Diagn Pathol       Date:  2012-04-19       Impact factor: 2.644

8.  Clinical significance of SOX9 in human non-small cell lung cancer progression and overall patient survival.

Authors:  Chun-Hui Zhou; Li-Ping Ye; Shi-Xing Ye; Yan Li; Xin-Yin Zhang; Xin-Yu Xu; Li-Yun Gong
Journal:  J Exp Clin Cancer Res       Date:  2012-03-03

9.  SOX9: a stem cell transcriptional regulator of secreted niche signaling factors.

Authors:  Meelis Kadaja; Brice E Keyes; Mingyan Lin; H Amalia Pasolli; Maria Genander; Lisa Polak; Nicole Stokes; Deyou Zheng; Elaine Fuchs
Journal:  Genes Dev       Date:  2014-02-15       Impact factor: 11.361

10.  Comprehensive Registry of Esophageal Cancer in Japan, 2009.

Authors:  Yuji Tachimori; Soji Ozawa; Hodaka Numasaki; Mitsuhiro Fujishiro; Hisahiro Matsubara; Tsuneo Oyama; Masayuki Shinoda; Yasushi Toh; Harushi Udagawa; Takashi Uno
Journal:  Esophagus       Date:  2016-03-29       Impact factor: 4.230

View more
  3 in total

1.  Chromobox 2 Expression Predicts Prognosis After Curative Resection of Oesophageal Squamous Cell Carcinoma.

Authors:  Sei Ueda; Mitsuro Kanda; Yusuke Sato; Hayato Baba; Shunsuke Nakamura; Koichi Sawaki; Dai Shimizu; Satoru Motoyama; Tsutomu Fujii; Yasuhiro Kodera; Shuji Nomoto
Journal:  Cancer Genomics Proteomics       Date:  2020 Jul-Aug       Impact factor: 4.069

2.  microRNA-605 directly targets SOX9 to alleviate the aggressive phenotypes of glioblastoma multiforme cell lines by deactivating the PI3K/Akt pathway.

Authors:  Jianwu Jia; Jing Wang; Meifeng Yin; Yongdong Liu
Journal:  Onco Targets Ther       Date:  2019-07-08       Impact factor: 4.147

3.  Subcellular localization of HMGB1 in human cholangiocarcinoma: correlation with tumor stage.

Authors:  Nattawan Suwannakul; Kaoru Midorikawa; Chunping Du; Ya-Peng Qi; Jie Zhang; Bang-De Xiang; Mariko Murata; Ning Ma
Journal:  Discov Oncol       Date:  2021-11-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.